(Q39601528)

13 September 2017

title

Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells (English)

1 reference

13 September 2017

1 reference

1 reference

Deyao Wu

1

1 reference

13 September 2017

Jun Tao

2

1 reference

13 September 2017

Bin Xu

3

1 reference

13 September 2017

Weijie Qing

4

1 reference

13 September 2017

Pengchao Li

5

1 reference

13 September 2017

Qiang Lu

6

1 reference

13 September 2017

Wei Zhang

7

1 reference

13 September 2017

publication date

27 January 2011

1 reference

13 September 2017

published in

Urologia Internationalis

1 reference

13 September 2017

volume

86

1 reference

13 September 2017

issue

3

1 reference

13 September 2017

page(s)

346-354

1 reference

13 September 2017

cites work

Cancer statistics, 2009

1 reference

Emerging targeted therapies for bladder cancer: a disease waiting for a drug

21 January 2018

1 reference

Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression

21 January 2018

1 reference

The role of PI3K in immune cells

21 January 2018

1 reference

The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation.

21 January 2018

1 reference

Effects of LY294002 on the invasiveness of human gastric cancer in vivo in nude mice

21 January 2018

1 reference

Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line

21 January 2018

1 reference

Overexpression of cFLIPs inhibits oxaliplatin-mediated apoptosis through enhanced XIAP stability and Akt activation in human renal cancer cells

21 January 2018

1 reference

LY294002 inhibits leukemia cell invasion and migration through early growth response gene 1 induction independent of phosphatidylinositol 3-kinase-Akt pathway

21 January 2018

1 reference

Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis

21 January 2018

1 reference

Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells

21 January 2018

1 reference

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

21 January 2018

1 reference

PI3K regulatory subunits lose control in cancer.

21 January 2018

1 reference

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.

21 January 2018

1 reference

Immunotherapy for superficial bladder cancer

21 January 2018

1 reference

Intravesical treatments of bladder cancer: review.

21 January 2018

1 reference

Furosemide reverses multidrug resistance status in bladder cancer cells in vitro

21 January 2018

1 reference

Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells

21 January 2018

1 reference

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

21 January 2018

1 reference

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts

21 January 2018

1 reference

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations

21 January 2018

1 reference

OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells

21 January 2018

1 reference

A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

21 January 2018

1 reference

Discovery of a novel class of AKT pleckstrin homology domain inhibitors

21 January 2018

1 reference

PI3K/Akt/mTOR pathway as a target for cancer therapy

21 January 2018

1 reference

Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xe

21 January 2018

1 reference

Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of leukaemia cells with an active PI3K/AKT pathway

21 January 2018

1 reference

UGT1A7 haplotype is associated with an increased risk of hepatocellular carcinoma in hepatitis B carriers

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000322986

1 reference

13 September 2017

1 reference